Literature DB >> 15831849

Drugs for Alzheimer's disease and related dementias.

Serge Gauthier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15831849      PMCID： PMC556143          DOI： 10.1136/bmj.330.7496.857

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

Review 1.  Pharmacologic management of agitation in Alzheimer's disease.

Authors:  Louis A Profenno; Pierre N Tariot
Journal:  Dement Geriatr Cogn Disord       Date:  2003-10-15       Impact factor: 2.959

2.  Behavioral problems in dementia: a factor analysis of the neuropsychiatric inventory.

Authors:  Pauline Aalten; Marjolein E de Vugt; Richel Lousberg; Edith Korten; Niek Jaspers; Birgit Senden; Jelle Jolles; Frans R J Verhey
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959

3.  Rivastigmine for dementia associated with Parkinson's disease.

Authors:  Murat Emre; Dag Aarsland; Alberto Albanese; E Jane Byrne; Günther Deuschl; Peter P De Deyn; Franck Durif; Jaime Kulisevsky; Teus van Laar; Andrew Lees; Werner Poewe; Alain Robillard; Mario M Rosa; Erik Wolters; Peter Quarg; Sibel Tekin; Roger Lane
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

4.  Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.

Authors:  Clive Ballard; Marisa Margallo-Lana; Edmund Juszczak; Simon Douglas; Alan Swann; Alan Thomas; John O'Brien; Anna Everratt; Stuart Sadler; Clare Maddison; Lesley Lee; Carol Bannister; Ruth Elvish; Robin Jacoby
Journal:  BMJ       Date:  2005-02-18

5.  A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Authors:  P N Tariot; J L Cummings; I R Katz; J Mintzer; C A Perdomo; E M Schwam; E Whalen
Journal:  J Am Geriatr Soc       Date:  2001-12       Impact factor: 5.562

6.  Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

Authors:  Serge Gauthier; Howard Feldman; Jane Hecker; Bruno Vellas; David Ames; Ponni Subbiah; Edward Whalen; Birol Emir
Journal:  Int Psychogeriatr       Date:  2002-12       Impact factor: 3.878

7.  Assessment of agitation in elderly patients with dementia: correlations between informant rating and direct observation.

Authors:  Jiska Cohen-Mansfield; Alexander Libin
Journal:  Int J Geriatr Psychiatry       Date:  2004-09       Impact factor: 3.485

8.  Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction.

Authors:  V Senanarong; J L Cummings; L Fairbanks; M Mega; D M Masterman; S M O'Connor; T L Strickland
Journal:  Dement Geriatr Cogn Disord       Date:  2003-10-13       Impact factor: 2.959

9.  Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.

Authors:  Jorge L Juncos; Vicki J Roberts; Marian L Evatt; Rita D Jewart; Colleen D Wood; Larry S Potter; Hann-Chang Jou; Paul P Yeung
Journal:  Mov Disord       Date:  2004-01       Impact factor: 10.338
  9 in total
  2 in total

Review 1.  Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.

Authors:  Florian Ferreri; Catherine Agbokou; Serge Gauthier
Journal:  J Psychiatry Neurosci       Date:  2006-11       Impact factor: 6.186

Review 2.  Management of the behavioral and psychological symptoms of dementia.

Authors:  Elizabeth C Hersch; Sharon Falzgraf
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.